Searched for
LUPIN QUARTERLY EARNINGS
Lupin Q1 PAT rises 16 pc at Rs 1,417 crLupin Ltd has reported a remarkable sixteen percent surge in profit after tax for the first quarter, showcasing their continued success. Th...- Inside LIC’s Rs 16 lakh crore portfolio: Its biggest stock buys and sells in June quarterLife Insurance Corporation bought shares worth over Rs 16,000 crore in June. Bharti Airtel and Maruti Suzuki saw the largest buying from th...
- Q1 earnings this week: SBI, Trent, Nykaa among 573 companies set to announce June quarter resultsThis week, 573 companies will announce their June quarter results, featuring prominent firms. Bharti Airtel and Nykaa are among those repor...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Lupin Q1 Results: Net profit surges 77% to Rs 801 croreLupin Q1 Results: Lupin's consolidated net profit surged by 77% to Rs 801 crore in the first quarter ending June 30, 2024, fueled by strong...
- Analysts bearish on 'expensive' Lupin after Q3 disappoints, stock falls 9%Of the 44 analysts, 18 of them have a 'sell' rating while 15 remain neutral. On aggregate, analysts slashed consensus price targets by 4.35...
- Lupin Q3 Results: Net profit declines 72% YoY to Rs 153.5 croreThe earnings before interest, tax, depreciation and amortisation (EBITDA) increased 44% YoY to Rs 532.7 crore for the quarter, with EBITDA ...
- Neutral on Lupin, target price Rs 1320: Motilal OswalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 55707.38 Crore) operating in Pharmaceuticals s...
- Neutral on Lupin, target price Rs 1320: Motilal OswalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 54321.39 Crore) operating in Pharmaceuticals s...
- Trending stocks: Lupin shares gain nearly 1%A total of 15,727 shares changed hands on the counter till 09:36AM.
- Key takeaways from Lupin’s Q3 earningsUS sales jumped 13.50 per cent QoQ to Rs 1417.40 crore in Q3FY19.
- Lupin's weak Q1 nos take toll: Brokerages cut target priceAnalysts expect the current financial year to be challenging for the company in terms of US sales.
- Credit Suisse sees Lupin’s EPS hit as Fortamet, Glumetza losing volume sharePrescriptions for Fortamet and Glumetza market are down 13% QoQ (quarter on quarter), which could impact FY18 EPS for Lupin by 5%.
- Underperform Lupin Ltd., target Rs 1500.0 : CLSAThe competition in the top US products segment is likely to weigh on Lupin's FY18 EPS growth, said the CLSA note.
- More USFDA nods to sustain Lupin’s good runThe stock closed 0.6% higher for the day following a higher-than-expected performance even as the BSE Healthcare index closed 0.5% lower an...
- It may take another quarter for Lupin to post a robust showMumbaibased pharma company Lupin has posted better-than-expected numbers after reporting dismal figures for four successive quarters.
- Rising local sales, strong drug pipeline may nurse Lupin back to healthAfter a stellar show in earlier years, where it grew an average 20 per cent annually , it has been difficult for Lupin to sustain growth.
- Local manufacturing can boost margins for LupinFor a fairly consistent performer in terms of top line growth in the pharma industry, drug maker Lupin’s show in the quarter to December wa...
- This growth co is commanding fair valuationsFuelled by strong growth across its various business segments, Lupin’s third quarter performance beat the market expectations.
Load More
